Percheron Therapeutics Limited has released a press release.
Trial Met Primary & Exceeded Secondary Endpoint Expectations
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Appointment of US-based Consultant Medical Director
- Results in DMD unlock value creation potential of ATL1102
- Quarterly Update & Appendix 4C
- Antisense Therapeutics Limited - Listed Options raise $5.5M
- Positive results reaffirm plans to advance ATL1102 to P2b
Later from Percheron Therapeutics
- EMA DMD Scientific Advice and Regulatory Process Update
- ANP Submits US Orphan Drug application for ATL1102 in DMD
- ANP Submits EU Orphan Drug application for ATL1102 in DMD
- Antisense to present new data at WMS Virtual Congress 2020
- US FDA Grants RPDD to ATL1102 for the treatment of DMD
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics